TARS · Tarsus Pharmaceuticals, Inc. · Debt

$70.20 -0.56 (-0.79%) Q2 2026 earnings call transcript

Market Cap

$3.15B

43.88M

Volume · Oct 27 747.97K Avg daily vol (3M) 843.45K

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Long-term debt, including current maturities	2026-06-30	USD 72,762,000	10-Q filed 2026-08-06
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Noncurrent debt carrying amount USD 72,762,000
Operating lease liabilities	2026-06-30	USD 16,049,000	10-Q filed 2026-08-06
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 154,000 Noncurrent operating lease liabilities USD 15,895,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1819790 CUSIP 87650L103 13F (30d) 33 filings 33 filers Visit website Investor relations